KUALA LUMPUR, July 10 (Bernama) -- Celgene Corp and Acceleron Pharma Inc have announced results from a "phase III, randomized, double-blind, multi-center clinical study (BELIEVE) ".
Luspatercept achieved a highly statistically significant improvement in the primary endpoint of erythroid response, which was defined as at least a 33 per cent reduction from baseline in red blood cell (RBC) transfusion burden compared to placebo.
Luspatercept is a first-in-class erythroid maturation agent (EMA) that is believed to regulate late-stage red blood cell maturation, a statement said.
The study evaluated the efficacy and safety of luspatercept plus best supportive care versus placebo plus best supportive care in adults with transfusion-dependent beta-thalassemia.
"For decades, the management of beta-thalassemia in adults has been limited to transfusions and iron chelation.
Reduction of transfusion burden represents an important step forward for patients with this rare and debilitating blood disease, " said Chief Medical Officer for Celgene, Jay Backstrom.
"The study marks the second positive phase III study for luspatercept and underscores the potential of this erythroid maturation agent to impact a range of diseases associated with chronic anemia, " said President and Chief Executive Officer of Acceleron, Habib Dable.
Celgene Corp is an integrated global biopharmaceutical company, headquartered in Summit, New Jersey while Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases.
More details on www.celgene.com and www.acceleronpharma.com
--BERNAMA
No comments:
Post a Comment